Patricia Andrews Acquires 35,400 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Patricia Andrews acquired 35,400 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were purchased at an average price of $0.86 per share, with a total value of $30,444.00. Following the acquisition, the director owned 78,128 shares of the company’s stock, valued at approximately $67,190.08. This represents a 82.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oncolytics Biotech Trading Down 2.2%

Shares of ONCY stock opened at $0.83 on Friday. The firm has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $1.07. Oncolytics Biotech Inc. has a 12 month low of $0.33 and a 12 month high of $1.51. The firm has a market capitalization of $88.60 million, a PE ratio of -2.98 and a beta of 0.99.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. On average, equities analysts predict that Oncolytics Biotech Inc. will post -0.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ONCY has been the subject of a number of recent research reports. Wall Street Zen lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. HC Wainwright lifted their price objective on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Finally, Zacks Research upgraded shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Oncolytics Biotech currently has an average rating of “Moderate Buy” and an average target price of $6.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ONCY. Scientech Research LLC bought a new position in Oncolytics Biotech in the 3rd quarter valued at $25,000. Seeds Investor LLC boosted its holdings in shares of Oncolytics Biotech by 17.8% in the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after buying an additional 33,826 shares during the last quarter. Ground Swell Capital LLC purchased a new position in shares of Oncolytics Biotech in the 4th quarter worth about $30,000. CIBC Private Wealth Group LLC bought a new position in Oncolytics Biotech during the fourth quarter valued at about $44,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in Oncolytics Biotech during the fourth quarter worth about $63,000. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.